派林生物：子公司获静注人免疫球蛋白药品补充申请受理通知书

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Guangdong Shuanglin Biological Pharmaceutical Co., Ltd., has received the acceptance notice for the supplemental application of intravenous immunoglobulin from the National Medical Products Administration, which is expected to enhance the safety and convenience of clinical medication and align domestic product processes with international standards [1] Group 1 - The application involves three specifications of intravenous immunoglobulin: 2.5g/bottle (10%, 25ml), 5g/bottle (10%, 50ml), and 10g/bottle (10%, 100ml) [1] - The main indications for the drug include primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1] - The acceptance of this application is anticipated to improve clinical medication safety and convenience [1]